We thank Dr. Zhao, Dr. Liao and Dr. Fan for their commentary on our SEAL study funded
by the Federal Joint Committee, the highest decision-making body of the self-government
of physicians, hospitals and health insurance funds in Germany, and published in the
Journal of Hepatology.
[1]
,[2]
In SEAL (Structured Early detection of Asymptomatic Liver cirrhosis), we were able
to demonstrate that screening for cirrhosis and advanced fibrosis in the general population
is feasible and that our approach has the potential to increase the early detection
rate of these patients.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Structured early detection of asymptomatic liver cirrhosis: results of the population-based liver screening program SEAL.J Hepatol. 2022; 77: 695-701
- An individualized cirrhosis screening strategy might be more cost-effective in the general population.J Hepatol. 2022; 77: 1728-1729https://doi.org/10.1016/j.hep.2022.06.035
- Does screening for liver fibrosis change alcohol consumption, died, and exercise? A prospective cohort study on the consequences of screening in 2,764 individuals.J Hepatol. 2022; 77: S35
Article info
Publication history
Published online: August 18, 2022
Accepted:
August 9,
2022
Received:
July 31,
2022
Footnotes
Author names in bold designate shared co-first authorship
Identification
Copyright
© 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
